Compare Ishares Msci Brazil ETF (EWZ) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Brazil ETF vs Revvity Inc — how do they compare? Ishares Msci Brazil ETF trades at $43.5 (market cap $11.30B), while Revvity Inc trades at $154.1 (market cap $16.98B). The key difference: Revvity Inc is the larger of the two by market cap, and Revvity Inc pays a 0.18% dividend while Ishares Msci Brazil ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Brazil ETF for 50 Days and Revvity Inc for 12 Days on average.
| EWZ | RVTY | |
|---|---|---|
Market Cap | $11.30B | $16.98B |
Volume | 44,036,597 | 1,456,900 |
Sector | Broad Market / Factor | Health |
52-Week High | $43.00 | $157.36 |
52-Week Low | $28.79 | $82.26 |
Typical Hold Time | 50 Days | 12 Days |
Enterprise Value | — | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWZ, the iShares MSCI Brazil ETF, is trading at $43.465, up 2.58% with a bullish technical signal from moving averages but bearish oscillators. The ETF shows strong institutional interest with unusual options activity and new positions from firms like Empowered Funds. Recent news highlights Brazil's upcoming election as a key market driver, with investors positioning for potential policy shifts under different candidates.
The outlook for EWZ hinges on Brazil's political landscape and commodity trends. Investment opportunities include geographic diversification and exposure to Brazilian stimulus policies, while risks involve election volatility and US-Brazil trade tensions. Wall Street shows cautious optimism with significant institutional accumulation despite competitive pressure from lower-fee alternatives like FLBR.
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
